



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/718,077

11/20/2003

Dave Dickason

CP185B

8643

27573

7590

10/13/2009

Ross J. Oehler
CEPHALON, Inc.
41 MOORES ROAD
PO BOX 4011
FRAZER, PA 19355

EXAMINER

KAROL, JODY LYNN

ART UNIT

PAPER NUMBER

1627

MAIL DATE

DELIVERY MODE

10/13/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/718,077	Applicant(s) DICKASON ET AL.	
	Examiner Jody L. Karol	Art Unit 1627	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 6/16/2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3, 6-9 and 11-46 is/are pending in the application.
- 4a) Of the above claim(s) 22-46 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 6-9, and 11-21 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt is acknowledged of applicant's Amendment/Remarks filed 6/16/2009. Claims 11 and 45-46 have been amended. Claim 10 has been cancelled, and claims 4-5 were previously cancelled. Claims 22-46 remain withdrawn as pertaining to the non-elected invention. Thus, claims 1-3, 6-9, and 11-46 are pending, and claims 1-3, 6-9, and 11-21 are currently under consideration.

It is noted that claims 45-46 are withdrawn, and amended. However, the claims do not contain a proper status identifier. The status identifier should be "Withdrawn - Currently Amended" instead of "Withdrawn."

WITHDRAWN REJECTIONS

1. In view of Applicant's amendment to the instant specification, the objection to the specification for typographical errors is herein withdrawn.
2. In view of Applicant's cancellation of claim 10 and amendment to claim 11, the rejection of claims 10-13 under 35 U.S.C. 112, 2nd paragraph, as being indefinite, is herein withdrawn.
3. In view of Applicant's cancellation of claim 10, the rejections of claim 10 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over

Art Unit: 1627

claims 1-21 and 23 of U.S. Patent No. 6,200,968 B1 and claims 1-6 and 32-33 of U.S. Patent No. 6,660,729 B1 are herein withdrawn.

Response to Arguments

4. Applicant's arguments filed 6/16/2009 have been fully considered but they are not persuasive.

The Applicants disagree with the basis of the non-statutory double patenting and states that the non-statutory double patenting rejection can be overcome by the filing of a Terminal Disclaimer. In response, it is respectfully submitted that a Terminal Disclaimer has not been filed as of the date of this Office Action. Further, Applicant's arguments do not comply with 37 CFR 1.111(c) because they do not clearly point out the patentable novelty which he or she thinks the claims present in view of the state of the art disclosed by the references cited or the objections made. Applicants provide no reasoning as to why the double patenting rejection is improper.

Thus, for these reasons, Applicant's arguments are found unpersuasive. Said rejection is maintained.

REJECTIONS

5. The following rejections have been maintained from the previous Office Action dated 1/6/2009:

Double Patenting


6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 1-3, 6-9, and 11-21 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-21 and 23 of U.S. Patent No. 6,200,968 B1.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the patented claims (see claim 23 in particular) include compositions comprising a fused pyrrolocarbazole with the formula:



at least 20% (w/w) of polyoxyl stearate; and polyethylene glycol as claimed in the instant claim 1. Furthermore, the patented claims are also directed to compositions comprising 1 to 100 mg/ml or 1 to 50 mg/ml of the fused pyrrolocarbazole as claimed in the instant claims 2-3 (see patented claims 20-21).

The patented claims do not claim the different molecular weights of polyethylene glycols as claimed in the instant claims 6-9 and 14-21, or the ratios of polyethylene glycol to polyoxyl stearate as claimed in the instant claims 11-13 and 15-21.


It would have been obvious to one of ordinary skill in the art at the time of the invention to optimize the molecular weight of the polyethylene glycol and the ratio of polyethylene glycol, or mixture of different molecular weight polyethylene glycols, to polyoxyl stearate. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. *In re Aller*, 220 F.2d 454, 105 U.S.P.Q. 223, 235 (C.C.P.A. 1955).

Thus, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time it was made.

Art Unit: 1627

8. Claims 1-3, 6-9, and 11-21 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6 and 32-33 of U.S. Patent No. US 6,660,729 B1.

Although the conflicting claims are not identical, they are not patentably distinct from each other because patented claims (see claim 32 in particular) include compositions comprising a fused pyrrolocarbazole with the formula:



at least 20% (w/w) of polyoxyl stearate; and polyethylene glycol as claimed in the instant claim 1. Furthermore, the patented claims are also directed to compositions comprising 1 to 100 mg/ml or 1 to 50 mg/ml of the fused pyrrolocarbazole as claimed in the instant claims 2-3 (see patented claims 2-3 and 5-6). Patented claim 33 is directed to a composition comprising a polyethylene glycol 400 as claimed in the instant claim 6-9 and a 50:50 ratio of the polyethylene glycol 400 to polyoxyl stearate as claimed in the instant claims 11-12.

The patented claims do not claim a ratio of polyethylene glycol to polyoxyl stearate of 80:20, mixtures of different molecular weight polyethylene glycols claimed in

Art Unit: 1627

the instant claims 14-21, or the ratio of the different molecular weight polyethylene glycols to polyoxyl stearate as claimed in the instant claims 15-21.

It would have been obvious to one of ordinary skill in the art at the time of the invention to optimize the molecular weight of the polyethylene glycol and the ratio of polyethylene glycol, or mixture of different molecular weight polyethylene glycols, to polyoxyl stearate. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. *In re Aller*, 220 F.2d 454, 105 U.S.P.Q. 223, 235 (C.C.P.A. 1955).

Thus, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time it was made.

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1627

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jody L. Karol whose telephone number is (571)270-3283. The examiner can normally be reached on 8:30 am - 5:00 pm Mon-Fri EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/Jody L. Karol/

Application/Control Number: 10/718,077

Page 9

Art Unit: 1627

Examiner, Art Unit 1617

/Yong S. Chong/

Primary Examiner, Art Unit 1627